JP2010111691A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010111691A5 JP2010111691A5 JP2010000195A JP2010000195A JP2010111691A5 JP 2010111691 A5 JP2010111691 A5 JP 2010111691A5 JP 2010000195 A JP2010000195 A JP 2010000195A JP 2010000195 A JP2010000195 A JP 2010000195A JP 2010111691 A5 JP2010111691 A5 JP 2010111691A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrocarbyl
- mixture
- aryl
- amino
- tautomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 20
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 17
- -1 amino, aminosulfinyl Chemical group 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 230000003463 hyperproliferative effect Effects 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 8
- 125000004404 heteroalkyl group Chemical group 0.000 claims 8
- 150000002431 hydrogen Chemical class 0.000 claims 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 125000002993 cycloalkylene group Chemical group 0.000 claims 7
- 241000124008 Mammalia Species 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 4
- 206010029113 Neovascularisation Diseases 0.000 claims 4
- 229910019142 PO4 Inorganic materials 0.000 claims 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 4
- 150000001540 azides Chemical class 0.000 claims 4
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 125000000018 nitroso group Chemical group N(=O)* 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 4
- 239000010452 phosphate Substances 0.000 claims 4
- ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical compound [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 claims 4
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims 4
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 claims 4
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- BUUPQKDIAURBJP-UHFFFAOYSA-N sulfinic acid Chemical compound OS=O BUUPQKDIAURBJP-UHFFFAOYSA-N 0.000 claims 4
- 229940124530 sulfonamide Drugs 0.000 claims 4
- 150000003456 sulfonamides Chemical class 0.000 claims 4
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 4
- 150000003462 sulfoxides Chemical class 0.000 claims 4
- 150000003573 thiols Chemical class 0.000 claims 4
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 1
- 206010055665 Corneal neovascularisation Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010065630 Iris neovascularisation Diseases 0.000 claims 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 claims 1
- 208000007135 Retinal Neovascularization Diseases 0.000 claims 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 201000000159 corneal neovascularization Diseases 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 150000002540 isothiocyanates Chemical class 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000001525 retina Anatomy 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39850402P | 2002-07-24 | 2002-07-24 | |
| US60/398,504 | 2002-07-24 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004523674A Division JP4468810B2 (ja) | 2002-07-24 | 2003-07-23 | ピラゾリルベンゾチアゾール誘導体および治療薬としてのそれらの使用法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010111691A JP2010111691A (ja) | 2010-05-20 |
| JP2010111691A5 true JP2010111691A5 (enExample) | 2012-06-07 |
| JP5405326B2 JP5405326B2 (ja) | 2014-02-05 |
Family
ID=31188411
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004523674A Expired - Fee Related JP4468810B2 (ja) | 2002-07-24 | 2003-07-23 | ピラゾリルベンゾチアゾール誘導体および治療薬としてのそれらの使用法 |
| JP2010000195A Expired - Fee Related JP5405326B2 (ja) | 2002-07-24 | 2010-01-04 | ピラゾリルベンゾチアゾール誘導体および治療薬としてのそれらの使用法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004523674A Expired - Fee Related JP4468810B2 (ja) | 2002-07-24 | 2003-07-23 | ピラゾリルベンゾチアゾール誘導体および治療薬としてのそれらの使用法 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US7847101B2 (enExample) |
| EP (1) | EP1542997B1 (enExample) |
| JP (2) | JP4468810B2 (enExample) |
| AT (1) | ATE547416T1 (enExample) |
| AU (1) | AU2003254650B2 (enExample) |
| CA (1) | CA2492964C (enExample) |
| DK (1) | DK1542997T3 (enExample) |
| ES (1) | ES2385378T3 (enExample) |
| WO (1) | WO2004011460A2 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1542997T3 (da) | 2002-07-24 | 2012-06-25 | Dermira Canada Inc | Pyrazolylbenzothiazolderivater og deres anvendelse som terapeutiske midler |
| MXPA06007326A (es) | 2003-12-23 | 2007-01-26 | Astex Therapeutics Ltd | Derivados de pirazol como moduladores de proteina cinasa. |
| US8343953B2 (en) | 2005-06-22 | 2013-01-01 | Astex Therapeutics Limited | Pharmaceutical compounds |
| JP5345842B2 (ja) | 2005-06-23 | 2013-11-20 | アステックス・セラピューティクス・リミテッド | プロテインキナーゼモジュレーターとしてのピラゾール誘導体を含む医薬組み合わせ |
| JP2009501164A (ja) * | 2005-07-15 | 2009-01-15 | ４エスツェー アクチェンゲゼルシャフト | ２−アリールベンゾチアゾール及びその使用 |
| EP2388263A1 (en) * | 2005-08-04 | 2011-11-23 | Sirtris Pharmaceuticals, Inc. | Imidazo[2,1-b]thiazole derivatives as sirtuin modulators |
| CA2618377A1 (en) | 2005-08-12 | 2007-02-22 | Synta Pharmaceuticals Corp. | Pyrazole compounds that modulate hsp90 activity |
| GB0704932D0 (en) | 2007-03-14 | 2007-04-25 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| TW200911240A (en) * | 2007-06-11 | 2009-03-16 | Kyowa Hakko Kogyo Kk | Anti-tumor agent |
| TW200916472A (en) | 2007-06-20 | 2009-04-16 | Sirtris Pharmaceuticals Inc | Sirtuin modulating compounds |
| EP2297134A1 (en) * | 2008-05-21 | 2011-03-23 | Basf Se | Substituted pyridin-4 -yl-methyl sulfonamides as fungicides |
| BRPI0913047A2 (pt) * | 2008-05-23 | 2013-03-05 | Siwa Corp | anticorpo monoclonal humanizado, seu uso, bem como aparelho e mÉtodo in vitro para promover processos regenerativos em uma cultura de tecido ou cultura de cÉlula |
| US9186349B2 (en) | 2009-05-12 | 2015-11-17 | Mallinckrodt Llc | Diaza heterocyclic compounds for phototherapy |
| US8731655B2 (en) | 2009-05-12 | 2014-05-20 | Mallinckrodt Llc | Compounds containing acyclic N-N bonds for phototherapy |
| JP5753844B2 (ja) | 2009-07-08 | 2015-07-22 | ダーミラ（カナダ），インコーポレーテッド | 皮膚疾患または病変の治療に有用なｔｏｆａ類似体 |
| WO2012047629A2 (en) | 2010-09-27 | 2012-04-12 | Siwa Corporation | Selective removal of age-modified cells for treatment of ather0sclerosis |
| US8721571B2 (en) | 2010-11-22 | 2014-05-13 | Siwa Corporation | Selective removal of cells having accumulated agents |
| US8658647B2 (en) | 2010-11-24 | 2014-02-25 | The Ohio State University Research Foundation | Integrin-linked kinase inhibitors |
| AR084032A1 (es) * | 2010-11-30 | 2013-04-17 | Takeda Pharmaceutical | Compuesto biciclico |
| LT6064B (lt) | 2012-10-15 | 2014-08-25 | Vilniaus Universitetas | Fluorinti benzensulfonamidai kaip karboanhidrazės inhibitoriai |
| CN102875486A (zh) * | 2012-11-02 | 2013-01-16 | 天津希恩思生化科技有限公司 | 2-苯并恶唑乙腈的制备方法 |
| CN102875541A (zh) * | 2012-11-02 | 2013-01-16 | 天津希恩思生化科技有限公司 | 3-(2-苯并恶唑基)-7-羟基香豆素的制备方法 |
| ITMI20132192A1 (it) * | 2013-12-23 | 2015-06-24 | Purisa S R L | Composti antimicrobici |
| JP2017513812A (ja) * | 2014-02-28 | 2017-06-01 | ザ ロイヤル インスティチューション フォー ジ アドヴァンスメント オブ ラーニング／マギル ユニヴァーシティ | 免疫療法用のａｐｃ活性剤としてのｔｃ−ｐｔｐ阻害剤 |
| IL251210B2 (en) | 2014-09-19 | 2023-12-01 | Siwa Corp | Anti-aging antibodies for the treatment of inflammation and autoimmune disorders |
| US10358502B2 (en) | 2014-12-18 | 2019-07-23 | Siwa Corporation | Product and method for treating sarcopenia |
| US9993535B2 (en) | 2014-12-18 | 2018-06-12 | Siwa Corporation | Method and composition for treating sarcopenia |
| PL3337829T3 (pl) | 2016-02-19 | 2020-05-18 | Siwa Corporation | Sposób i kompozycja do leczenia raka, zwalczania przerzutowych komórek nowotworowych i zapobiegania przerzutom nowotworowym przy użyciu przeciwciała przeciwko produktom końcowych zaawansowanej glikacji (AGE) |
| AU2017250301A1 (en) | 2016-04-15 | 2018-11-15 | Siwa Corporation | Anti-age antibodies for treating neurodegenerative disorders |
| JP2019518763A (ja) | 2016-06-23 | 2019-07-04 | シワ コーポレーション | 様々な疾患及び障害の治療において使用するためのワクチン |
| GB201617339D0 (en) * | 2016-10-12 | 2016-11-23 | Lytix Biopharma As | Therapeutic compounds |
| US10995151B1 (en) | 2017-01-06 | 2021-05-04 | Siwa Corporation | Methods and compositions for treating disease-related cachexia |
| US10925937B1 (en) | 2017-01-06 | 2021-02-23 | Siwa Corporation | Vaccines for use in treating juvenile disorders associated with inflammation |
| US10961321B1 (en) | 2017-01-06 | 2021-03-30 | Siwa Corporation | Methods and compositions for treating pain associated with inflammation |
| US10858449B1 (en) | 2017-01-06 | 2020-12-08 | Siwa Corporation | Methods and compositions for treating osteoarthritis |
| EP3609923A1 (en) | 2017-04-13 | 2020-02-19 | Siwa Corporation | Humanized monoclonal advanced glycation end-product antibody |
| US11518801B1 (en) | 2017-12-22 | 2022-12-06 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
| AU2019387370A1 (en) | 2018-11-30 | 2021-06-10 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| WO2020150306A1 (en) * | 2019-01-18 | 2020-07-23 | Vtv Therapeutics Llc | Substituted fused imidazole derivatives and methods of treating sickle cell disease and related complications |
| CN111559989B (zh) * | 2020-04-12 | 2022-09-09 | 青岛科技大学 | 一种可见光促进2-氨基萘并[2,1-d]噻唑类化合物的合成方法和应用 |
| WO2024003408A1 (en) * | 2022-07-01 | 2024-01-04 | Universität Zürich | Small-molecule inhibitors of the frs2-fgfr interaction |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS52108427A (en) * | 1976-03-10 | 1977-09-10 | Hodogaya Chem Co Ltd | Solubilization of dyes into aromatic hydrocarbon solvent |
| US4269846A (en) * | 1979-10-29 | 1981-05-26 | Usv Pharmaceutical Corporation | Heterocyclic compounds useful as anti-allergy agents |
| US5770592A (en) | 1991-11-22 | 1998-06-23 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization using angiostatic steroids |
| US5798349A (en) | 1994-03-14 | 1998-08-25 | The General Hospital Corporation | Use of green porphyrins to treat neovasculature in the eye |
| JP2961074B2 (ja) | 1995-09-06 | 1999-10-12 | 明治製菓株式会社 | 光化学療法用の新生血管閉塞剤 |
| US20020168761A1 (en) * | 2000-01-24 | 2002-11-14 | Gour Barbara J. | Peptidomimetic modulators of cell adhesion |
| US6043237A (en) | 1996-12-10 | 2000-03-28 | Qlt Phototherapeutics, Inc. | Use of photodynamic therapy for prevention of secondary cataracts |
| EP1006114B1 (en) | 1997-04-11 | 2003-01-22 | Grelan Pharmaceutical Co., Ltd. | Pyrazole derivatives and cox inhibitors containing them |
| US6214819B1 (en) | 1998-11-23 | 2001-04-10 | Novartis Ag | Method for treating ocular neovascular diseases |
| US6217895B1 (en) | 1999-03-22 | 2001-04-17 | Control Delivery Systems | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
| US6271233B1 (en) | 1999-08-10 | 2001-08-07 | Ciba Vision Corporation | Method for treating ocular neovascular diseases |
| US6436915B1 (en) * | 2000-04-07 | 2002-08-20 | Kinetek Pharmaceuticals, Inc. | Pyrazole compounds |
| GB0102687D0 (en) | 2001-02-02 | 2001-03-21 | Pharmacia & Upjohn Spa | Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them |
| RU2318824C2 (ru) * | 2001-11-09 | 2008-03-10 | Си Ви Терапьютикс, Инк. | Антагонисты рецептора аденозина a2b, фармацевтическая композиция на их основе и способ их получения |
| JP4399265B2 (ja) * | 2001-12-21 | 2010-01-13 | ヴァーナリス（ケンブリッジ）リミテッド | ３，４−ジアリールピラゾール、および癌の治療におけるそれらの使用 |
| GB0206860D0 (en) * | 2002-03-22 | 2002-05-01 | Glaxo Group Ltd | Compounds |
| DK1542997T3 (da) * | 2002-07-24 | 2012-06-25 | Dermira Canada Inc | Pyrazolylbenzothiazolderivater og deres anvendelse som terapeutiske midler |
-
2003
- 2003-07-23 DK DK03771002.7T patent/DK1542997T3/da active
- 2003-07-23 AT AT03771002T patent/ATE547416T1/de active
- 2003-07-23 JP JP2004523674A patent/JP4468810B2/ja not_active Expired - Fee Related
- 2003-07-23 US US10/521,948 patent/US7847101B2/en not_active Expired - Fee Related
- 2003-07-23 WO PCT/CA2003/001078 patent/WO2004011460A2/en not_active Ceased
- 2003-07-23 ES ES03771002T patent/ES2385378T3/es not_active Expired - Lifetime
- 2003-07-23 CA CA2492964A patent/CA2492964C/en not_active Expired - Fee Related
- 2003-07-23 AU AU2003254650A patent/AU2003254650B2/en not_active Expired - Fee Related
- 2003-07-23 EP EP03771002A patent/EP1542997B1/en not_active Expired - Lifetime
-
2010
- 2010-01-04 JP JP2010000195A patent/JP5405326B2/ja not_active Expired - Fee Related
- 2010-10-22 US US12/910,744 patent/US8410272B2/en not_active Expired - Fee Related
-
2013
- 2013-02-25 US US13/776,503 patent/US8754233B2/en not_active Expired - Fee Related
-
2014
- 2014-05-06 US US14/271,263 patent/US9434720B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010111691A5 (enExample) | ||
| ES2385378T3 (es) | Derivados de pirazolilbenzotiazol y su uso como agentes terapéuticos | |
| AU2007213451B2 (en) | Treatment of Duchenne muscular dystrophy | |
| JP2010510237A5 (enExample) | ||
| RU2005138719A (ru) | Новые бисамидатные фосфонатные пролекарства | |
| AU2011227398C1 (en) | Modulators of Hec1 activity and methods therefor | |
| ES2676585T3 (es) | Compuestos heterocíclicos y métodos de uso | |
| RU2013132389A (ru) | Фосфорные производные в качестве модуляторов хемокиновых рецепторов | |
| JP2010534706A5 (enExample) | ||
| JP2018519343A5 (enExample) | ||
| EA036001B1 (ru) | Комбинация эрлотиниба и ингибитора глутаминазы для лечения рака легких | |
| JP2011515398A5 (enExample) | ||
| JP2010519304A5 (enExample) | ||
| CA2796967A1 (en) | Heterocyclic derivatives as alk inhibitors | |
| CN101678107A (zh) | 用于治疗杜兴型肌营养不良的药物组合物 | |
| JP2013545798A5 (enExample) | ||
| RU2004104625A (ru) | Аналоги простагландинов в качестве агонистов рецептора ep4 | |
| JP2017527532A5 (enExample) | ||
| KR20140145203A (ko) | 포르밀 펩타이드 수용체 2 조절물질로서 (2-우레이도아세트아미도)알킬 유도체 | |
| JP2016529235A5 (enExample) | ||
| JP2014506582A5 (enExample) | ||
| CN114728910A (zh) | 用于fgfr抑制剂的吡唑类衍生物及其制备方法 | |
| AU2016355429B2 (en) | Nucleic acid prodrugs | |
| JP2018530582A5 (enExample) | ||
| JP2004525183A5 (enExample) |